

(12) International Application Status Report

Received at International Bureau: 15 October 2002 (15.10.2002)

Information valid as of: (..)

Report generated on: 17 September 2021 (17.09.2021)

(10) Publication number:

WO2003/024990

(43) Publication date:

27 March 2003 (27.03.2003)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/US2002/029117

(22) Filing Date:

13 September 2002 (13.09.2002)

(25) Filing language:

English (EN)

(31) Priority number(s):

60/322,195 (US)

(31) Priority date(s):

14 September 2001 (14.09.2001)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 38/00 (2006.01); *C07K 14/72* (2006.01)

(71) Applicant(s):

THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION [US/US]; 1534 White Avenue, Suite 403 Knoxville, TN 37996-1527 (US) *(for all designated states)*

(72) Inventor(s):

PISARCHIK, Alexander; 8275 Sturbridge Way Apt 4 Cordova, TN 38018 (US)
SLOMINSKI, Andrzej; 2417 Calkins Rd Germantown, TN 38139 (US)

(74) Agent(s):

ADLER, Benjamin, A.; Adler & Associates 8011 Candle Lane Houston, TX 77071 (US)

(54) Title (EN): VARIANTS OF CORTICOTROPIN RELEASING HORMONE RECEPTOR TYPE 1 AND USES THEREOF

(54) Title (FR): VARIANTS DU RECEPTEUR D'HORMONE DE LIBERATION DE LA CORTICOTROPINE DE TYPE 1, ET UTILISATIONS CORRESPONDANTES

(57) Abstract:

(EN): The present invention identifies four new isoforms of human corticotropin releasing hormone receptor type 1 (CRH-R1e, 1f, 1g and 1h) and three new isoforms of mouse corticotropin releasing hormone receptor type 1 (mCRH-R1c, 1e and 1f). The data indicate that polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, external stress (UV), and that cAMP dependent pathways and TPA may regulate CRH-R1.

(FR): L'invention concerne quatre isoformes du récepteur d'hormone de libération de la corticotropine de type 1 chez l'homme (CRH-R1e, 1f, 1g et 1h) et trois isoformes du récepteur de type 1 de ladite hormone chez la souris (mCRH-R1c, 1e et 1f). Les données recueillies dans l'identification de ces isoformes montrent que le polymorphisme de l'expression du CRH-R1 est lié aux critères suivants: emplacement anatomique, état physiologique ou pathologique de la peau, type de cellule spécifique, stress extérieur (rayonnement ultraviolet). Il apparaît en outre que les trajets dépendant de l'AMPc et le TPA peuvent réguler le CRH-R1.

International search report:

Received at International Bureau: 01 June 2004 (01.06.2004) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM